The research progress in the relationship between liver metastases of colorectal cancer and HBV infection, liver fibrosis

doi:10.3969/j.issn.1009-976X.2015.02.029

Abstract

Abstract: 【Abstract】〓Objective〓Colorectal cancer is one of the most common human malignancies, and the liver metastase of colorectal cancer is the main reason for death and disability. Multi-clinical analysis confirmed that HBV infection and cirrhosis decrease risk of liver metastasis in patients with colorectal cancer, but there is still no certain mechanism to explain the clinical phenoenon. In this paper, it is described that the possible related mechanism through epigenetic, tumor microenvironment and immunity.

Key words: Liver metastases of colorectal cancer, HBV, Liver cirrhosis, Mechanism

摘要： 【摘要】〓结直肠癌为人体最常见恶性肿瘤之一,而结直肠癌肝转移为致死致残的主要原因。多方临床分析证实乙型病毒性肝炎、肝硬化患者结直肠癌肝转移发生率较正常患者明显降低,且有统计学意义。目前仍无明确机制解释该临床现象,本文从临床分析结果出发,以肿瘤微环境、肿瘤免疫、表观遗传学为主,综述乙型病毒性肝炎、肝硬化患者结肠癌肝转移率低的相关可能机制,并作进一步机制讨论。

关键词: 结直肠癌肝转移, 乙肝病毒, 肝硬化, 机制

CLC Number:

R735.4

蓝球生褚忠华. 结直肠癌肝转移与乙肝病毒性肝炎及肝硬化关系研究进展[J]. 岭南现代临床外科, 2015, 15(02): 222-227.

References

[1]Siegel, R., C. Desantis and A. Jemal, Colorectal cancer statistics, 2014. CA Cancer J Clin, 2014. 64(2): p. 104-117. [2]Lee, W.S., et al., Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis, 2007. 22(6): p. 699-704. [3]Van Cutsem, E., et al., Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 2006. 42(14): p. 2212-2221. [4]Yoo, P.S., et al., Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer, 2006. 6(3): p. 202-207. [5]Muratore, A., et al., Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol, 2007. 14(2): p. 766-770. [6]Hayashi, M., et al., Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg, 2010. 10: p. 27. [7]Gervaz, P., et al., Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg, 2003. 196(6): p. 874-879. [8]Qiu, H.B., et al., HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol, 2011. 17(6): p. 804-808. [9]Utsunomiya, T., et al., Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Am J Surg, 1999. 177(4): p. 279-281. [10]Lisa, J.R., C. Solomon and E.J. Gordon, Secondary Carcinoma in Cirrhosis of the Liver. Am J Pathol, 1942. 18(1): p. 137-140. [11]Uetsuji, S., et al., Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg, 1992. 164(2): p. 176-177. [12]Seymour, K.and R.M. Charnley, Evidence that metastasis is less common in cirrhotic than normal liver: a systematic review of post-mortem case-control studies. Br J Surg, 1999. 86(10): p. 1237-1242. [13]Uetsuji, S., et al., Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg, 1992. 164(2): p. 176-177. [14]Utsunomiya, T., et al., Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Am J Surg, 1999. 177(4): p. 279-281. [15]Song, E., et al., Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. Am J Surg, 2001. 181(6): p. 529-533. [16]Cui, Y.and J. Jia, Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol, 2013. 28 Suppl 1: p. 7-10. [17]Psaila, B.and D. Lyden, The metastatic niche: adapting the foreign soil. Nat Rev Cancer, 2009. 9(4): p. 285-293. [18]Morgan, S.C. and C.C. Parker, Local treatment of metastatic cancer--killing the seed or disturbing the soil? Nat Rev Clin Oncol, 2011. 8(8): p. 504-506. [19]Sung, S.Y., et al., Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer, 2007. 31(2): p. 36-100. [20]Lisa, J.R., C. Solomon and E.J. Gordon, Secondary Carcinoma in Cirrhosis of the Liver. Am J Pathol, 1942. 18(1): p. 137-140. [21]LIEBER, M.M., The rare occurrence of metastatic carcinoma in the cirrhotic liver. Am J Med Sci, 1957. 233(2): p. 145-152. [22]Hamaya, K., H. Hashimoto and Y. Maeda, Metastatic carcinoma in cirrhotic liver--Statistical survey of autopsies in Japan. Acta Pathol Jpn, 1975. 25(2): p. 153-159. [23]Scoazec, J.Y., Expression of cell-matrix adhesion molecules in the liver and their modulation during fibrosis. J Hepatol, 1995. 22(2 Suppl): p. 20-27. [24]Gervaz, P., et al., Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg, 2003. 196(6): p. 874-879. [25]Llorent, L., et al., Cytokine gene expression in cirrhotic and non-cirrhotic human liver. J Hepatol, 1996. 24(5): p. 555-563. [26]Consolo, M., et al., Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med, 2009. 24(2): p. 143-152. [27]Urtasun, R., D.L.R.L. Conde and N. Nieto, Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis, 2008. 12(4): p. 769-790, viii. [28]Badra, G., et al., Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung, 2010. 57(1): p. 29-42. [29]Islekel, H., et al., Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct, 2007. 25(4): p. 433-441. [30]Dunn, G.P., et al., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 2002. 3(11): p. 991-998. [31]Schreiber, R.D., L.J. Old and M.J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011. 331(6024): p. 1565-1570. [32]Yoffe, B., et al., Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection. Hepatology, 1990. 12(2): p. 187-192. [33]Mason, A., et al., Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology, 1993. 18(4): p. 781-789. [34]Neurath, A.R., et al., Detection of receptors for hepatitis B virus on cells of extrahepatic origin. Virology, 1990. 176(2): p. 448-457. [35]Doherty, D.G., et al., The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol, 1999. 163(4): p. 2314-2321. [36]McDonald, B., et al., Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer, 2009. 125(6): p. 1298-1305. [37]Lara-Pezzi, E., et al., The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology, 1998. 28(4): p. 1013-1021. [38]Song, E., et al., Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis. Br J Cancer, 2001. 84(9): p. 1265-1271. [39]Rushfeldt, C., et al., Early events of hepatic metastasis formation in mice: role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. J Surg Res, 1999. 82(2): p. 209-215. [40]Tsujimoto, T., et al., Augmented hepatocellular carcinoma progression and depressed Kupffer cell activity in rat cirrhotic livers. Int J Oncol, 2001. 18(1): p. 41-47. [41]Kaufmann, T., A. Strasser and P.J. Jost, Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ, 2012. 19(1): p. 42-50. [42]Moulian, N., et al., Functional Fas expression in human thymic epithelial cells. Blood, 1999. 93(8): p. 2660-2670. [43]Yang, C., H.Z. Liu and Z.X. Fu, PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase-8. Cell Biol Int, 2012. 36(3): p. 289-296. [44]McDermott, U., et al., Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res, 2005. 65(19): p. 8951-8960. [45]Li, H., et al., Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology, 2009. 137(3): p. 934-944, 944.e1-4. [46]徐彤, 李强与郝希山, 大肠癌细胞功能性Fas配体的表达度与肿瘤免疫逃逸的关系.世界华人消化杂志, 2004(09): 第56-59页. [47]Thiery, J.P., et al., Epithelial-Mesenchymal Transitions in Development and Disease. Cell, 2009. 139(5): p. 871-890. [48]Thiery, J.P. and J.P. Sleeman, Complex networks orchestrate epithelial–mesenchymal transitions. Nature Reviews Molecular Cell Biology, 2006. 7(2): p. 131-142. [49]Yilmaz, M.and G. Christofori, Mechanisms of Motility in Metastasizing Cells. Molecular Cancer Research, 2010. 8(5): p. 629-642. [50]Hosel, M., et al., Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology, 2009. 50(6): p. 1773-1782. [51]Li, H., et al., Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-beta1 over pro-inflammatory cytokines. Dig Liver Dis, 2012. 44(4): p. 328-333. [52]Hagen, T.M., et al., Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A, 1994. 91(26): p. 12808-1212. [53]You, Q., et al., Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology, 2008. 48(3): p. 978-990. [54]Tordjmann, T., et al., Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Liver, 1998. 18(6): p. 391-397. [55]Yu, H., et al., The contribution of TGF-beta in Epithelial-Mesenchymal Transition (EMT): Down-regulation of E-cadherin via snail. Neoplasma, 2015. 62(1): p. 1-15. [56]Xu, H., et al., Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer, 2014. 14(1): p. 330. [57]Maheswaran, T.and S.M. Rushbrook, Epithelial-mesenchymal transition and the liver: Role in hepatocellular carcinoma and liver fibrosis. Journal of Gastroenterology and Hepatology, 2012. 27(3): p. 418-420. [58]Wallace, K., A.D. Burt and M.C. Wright, Liver fibrosis. Biochemical Journal, 2008. 411(1): p. 1. [59]Liao, Y., et al., Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death and Disease, 2014. 5(3): p. e1137. [60]Chen, D., et al., Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology, 2014. 60(2): p. 598-609. [61]Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences, 2008. 105(30): p. 10513-10518. [62]Yu, F., et al., let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell, 2007. 131(6): p. 1109-1123. [63]Ru, P., et al., miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling. Molecular Cancer Therapeutics, 2012. 11(5): p. 1166-1173. [64]Huang, Z., et al., Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International Journal of Cancer, 2010. 127(1): p. 118-126. [65]Gregory, P.A., et al., The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 2008. 10(5): p. 593-601. [66]Jackstadt, R., et al., AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. Journal of Experimental Medicine, 2013. 210(7): p. 1331-1350. [67]Shi, L., et al., p53-Induced miR-15a/16-1 and AP4 Form a Double-Negative Feedback Loop to Regulate Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. Cancer Research, 2014. 74(2): p. 532-542. [68]Wu, F., et al., Targets for human encoded microRNAs in HBV genes. Virus Genes, 2011. 42(2): p. 157-161. [69]Wang, Y., et al., Hepatitis B Viral RNA Directly Mediates Down-regulation of the Tumor Suppressor MicroRNA miR-15a/miR-16-1 in Hepatocytes. Journal of Biological Chemistry, 2013. 288(25): p. 18484-18493. [70]Ura, S., et al., Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology, 2009. 49(4): p. 1098-1112. [71]Murakami, Y., et al., The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families. PLoS ONE, 2011. 6(1): p. e16081. [72]Li, W., et al., The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS Journal, 2011. 278(9): p. 1522-1532.